Advertisement

Asthma and the Biologics Revolution, Part 1: Here and Now

  • Babak Aberumand
  • Anne K. EllisEmail author
Allergic Asthma (DES Larenas-Linnemann de Martinez, Section Editor)
  • 1 Downloads
Part of the following topical collections:
  1. Topical Collection on Allergic Asthma

Abstract

Purpose of This Review

To highlight the evidence behind the various approved biologics indicated for asthma along with their specific targets in the inflammatory cascade and the role they serve in the management of allergic asthma.

Recent Findings

The mainstay of asthma management for the majority of asthmatics is inhaled corticosteroids with or without long-acting beta-agonists and/or leukotriene modifiers and/or tiotropium. However, in the small group of individuals with severe asthma uncontrolled with conventional therapy, biologics have emerged as an effective therapeutic option.

Summary

Asthma is a chronic heterogenous disease affecting both children and adults. In its severe form, asthma is associated with significant morbidity and mortality along with increased healthcare utilization and costs. Several biologics targeting different areas of the asthmatic inflammatory cascade have been approved and continue to be assessed for the management of severe allergic asthma. Uncovering the pathophysiology of asthma not only has identified potential targets for therapy but also has brought to light the importance of uncovering specific biomarkers that will help aid therapeutic decision-making.

Keywords

Biologics Asthma Anti-IgE Anti-IL-5 Anti-IL-4 and anti-IL-13 Omalizumab Xolair Mepolizumab Nucala Reslizumab Cinqair Benralizumab Fasenra 

Notes

Compliance with Ethical Standards

Conflict of Interest

Anne Ellis has participated in advisory boards for ALK Abello, Circassia Ltd., GlaxoSmithKline, Johnson & Johnson, Merck, and Novartis and has been a speaker for Aralez, AstraZeneca, Boehringer Ingelheim, Meda, Mylan, Merck, Novartis, Pediapharm, Pfizer, and Takeda. Her institution has received research grants from Circassia Ltd., Green Cross Pharmaceuticals, GlaxoSmithKline, Sanofi, Sun Pharma, Merck, Novartis, and Pfizer. Dr. Ellis is also a consultant to Bayer Inc. and reports personal fees from kaleo. Babak Aberumand declares no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma P. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–78.  https://doi.org/10.1111/j.1398-9995.2004.00526.x.CrossRefPubMedGoogle Scholar
  2. 2.
    Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–78.  https://doi.org/10.1183/13993003.51387-2007.CrossRefPubMedGoogle Scholar
  3. 3.
    Holt PG, Sly PD. Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis. Chest. 2011;139(5):1165–71.  https://doi.org/10.1378/chest.10-2397.CrossRefPubMedGoogle Scholar
  4. 4.
    Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004;92(1):32–9.  https://doi.org/10.1016/S1081-1206(10)61707-3.CrossRefPubMedGoogle Scholar
  5. 5.
    Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med. 1989;320(5):271–7.  https://doi.org/10.1056/NEJM198902023200502.CrossRefPubMedGoogle Scholar
  6. 6.
    Sihra BS, Kon OM, Grant JA, Kay AB. Expression of high-affinity IgE receptors (Fc epsilon RI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: relationship to total serum IgE concentrations. J Allergy Clin Immunol. 1997;99(5):699–706.  https://doi.org/10.1016/S0091-6749(97)70033-2.CrossRefPubMedGoogle Scholar
  7. 7.
    Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546–56.  https://doi.org/10.1172/JCI36130.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73.  https://doi.org/10.1183/09031936.00202013.CrossRefPubMedGoogle Scholar
  9. 9.
    Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002;19(1):61–7.  https://doi.org/10.1183/09031936.02.00232001.CrossRefPubMedGoogle Scholar
  10. 10.
    Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205–17.  https://doi.org/10.1038/nri2273.CrossRefPubMedGoogle Scholar
  11. 11.
    Haselkorn T, Borish L, Miller DP, Weiss ST, Wong DA. High prevalence of skin test positivity in severe or difficult-to-treat asthma. J Asthma. 2006;43(10):745–52.  https://doi.org/10.1080/02770900601031540.CrossRefPubMedGoogle Scholar
  12. 12.
    Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693–704.  https://doi.org/10.1038/nm.2755.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018;12:1753466618810192.  https://doi.org/10.1177/1753466618810192.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Novartis Pharmaceuticals Canada Inc. Xolair (omalizumab) product monograph. Date of approval 25, 2015Google Scholar
  15. 15.
    Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–93.  https://doi.org/10.1164/rccm.200312-1651OC.CrossRefPubMedGoogle Scholar
  16. 16.
    Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155(6):1828–34.  https://doi.org/10.1164/ajrccm.155.6.9196082.CrossRefPubMedGoogle Scholar
  17. 17.
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184–90.  https://doi.org/10.1067/mai.2001.117880.CrossRefPubMedGoogle Scholar
  18. 18.
    Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254–61.  https://doi.org/10.1183/09031936.01.00092101.CrossRefPubMedGoogle Scholar
  19. 19.
    Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4):632–8.  https://doi.org/10.1111/j.1365-2222.2004.1916.x.CrossRefPubMedGoogle Scholar
  20. 20.
    Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–16.  https://doi.org/10.1111/j.1398-9995.2004.00772.x.CrossRefPubMedGoogle Scholar
  21. 21.
    Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573–82.  https://doi.org/10.7326/0003-4819-154-9-201105030-00002.CrossRefPubMedGoogle Scholar
  22. 22.
    Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–11.  https://doi.org/10.1164/rccm.201208-1414OC.CrossRefPubMedGoogle Scholar
  23. 23.
    Busse W, Spector S, Rosen K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132(2):485–6 e11.  https://doi.org/10.1016/j.jaci.2013.02.032.CrossRefGoogle Scholar
  24. 24.
    Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483–92.  https://doi.org/10.1016/j.rmed.2007.01.011.CrossRefPubMedGoogle Scholar
  25. 25.
    Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210–6.  https://doi.org/10.1016/j.jaci.2009.09.021.CrossRefPubMedGoogle Scholar
  26. 26.
    Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–15.  https://doi.org/10.1056/NEJMoa1009705.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103(11):1633–42.  https://doi.org/10.1016/j.rmed.2009.06.014.CrossRefPubMedGoogle Scholar
  28. 28.
    Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141–51.  https://doi.org/10.1016/j.rmed.2013.04.017.CrossRefPubMedGoogle Scholar
  29. 29.
    Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013;143(2):398–405.  https://doi.org/10.1378/chest.12-1372.CrossRefPubMedGoogle Scholar
  30. 30.
    Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156–64 e1.  https://doi.org/10.1016/j.jaip.2018.04.043.PubMedGoogle Scholar
  31. 31.
    Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.  https://doi.org/10.1002/14651858.CD003559.pub4.CrossRefGoogle Scholar
  32. 32.
    Domingo C, Moreno A, Jose Amengual M, Monton C, Suarez D, Pomares X. Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients. Curr Med Res Opin. 2011;27(1):45–53.  https://doi.org/10.1185/03007995.2010.536208.CrossRefPubMedGoogle Scholar
  33. 33.
    Nopp A, Johansson SG, Adedoyin J, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65(1):56–60.  https://doi.org/10.1111/j.1398-9995.2009.02144.x.CrossRefPubMedGoogle Scholar
  34. 34.
    • Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosen K, Chipps BE, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–9 e2.  https://doi.org/10.1016/j.jaci.2016.08.054 This study provides the long-term effects of omalizumab after discontinuation.CrossRefGoogle Scholar
  35. 35.
    Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788–97.  https://doi.org/10.1111/j.1365-2222.2009.03214.x.CrossRefPubMedGoogle Scholar
  36. 36.
    Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol. 2007;120(6):1378–81.  https://doi.org/10.1016/j.jaci.2007.09.022.CrossRefPubMedGoogle Scholar
  37. 37.
    Cox L, Lieberman P, Wallace D, Simons FE, Finegold I, Platts-Mills T, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol. 2011;128(1):210–2.  https://doi.org/10.1016/j.jaci.2011.04.01.CrossRefPubMedGoogle Scholar
  38. 38.
    Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560–7 e4.  https://doi.org/10.1016/j.jaci.2014.02.007.CrossRefGoogle Scholar
  39. 39.
    Cooper PJ, Ayre G, Martin C, Rizzo JA, Ponte EV, Cruz AA. Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy. 2008;63(4):409–17.  https://doi.org/10.1111/j.1398-9995.2007.01601.x.CrossRefPubMedGoogle Scholar
  40. 40.
    Kuno K, Matsushima K. The IL-1 receptor signaling pathway. J Leukoc Biol. 1994;56(5):542–7.  https://doi.org/10.1002/jlb.56.5.542.CrossRefPubMedGoogle Scholar
  41. 41.
    Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy. 2012;42(5):712–37.  https://doi.org/10.1111/j.1365-2222.2011.03854.x.CrossRefPubMedGoogle Scholar
  42. 42.
    Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov. 2013;12(2):117–29.  https://doi.org/10.1038/nrd3838.CrossRefPubMedGoogle Scholar
  43. 43.
    Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–71.  https://doi.org/10.1164/rccm.200701-085OC.CrossRefPubMedGoogle Scholar
  44. 44.
    GlaxoSmithKline Inc. Nucala (mepolizumab) product monograph. Date of approval, 2016.Google Scholar
  45. 45.
    Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–84.  https://doi.org/10.1056/NEJMoa0808991.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–93.  https://doi.org/10.1056/NEJMoa0805435.CrossRefPubMedGoogle Scholar
  47. 47.
    Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–9.  https://doi.org/10.1016/S0140-6736(12)60988-X.CrossRefPubMedGoogle Scholar
  48. 48.
    Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207.  https://doi.org/10.1056/NEJMoa1403290.CrossRefPubMedGoogle Scholar
  49. 49.
    Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–97.  https://doi.org/10.1056/NEJMoa1403291.CrossRefPubMedGoogle Scholar
  50. 50.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400.  https://doi.org/10.1016/S2213-2600(17)30125-X.CrossRefPubMedGoogle Scholar
  51. 51.
    Teva Canada Limited. Cinqair (reslizumab) product monograph. Date of approval: March 16, 2017.Google Scholar
  52. 52.
    Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–32.  https://doi.org/10.1164/rccm.201103-0396OC.CrossRefPubMedGoogle Scholar
  53. 53.
    Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66.  https://doi.org/10.1016/S2213-2600(15)00042-9.CrossRefPubMedGoogle Scholar
  54. 54.
    Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–98.  https://doi.org/10.1016/j.chest.2016.03.032.CrossRefPubMedGoogle Scholar
  55. 55.
    Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810.  https://doi.org/10.1016/j.chest.2016.03.018.CrossRefPubMedGoogle Scholar
  56. 56.
    Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–53 e2.  https://doi.org/10.1016/j.jaci.2010.04.004.CrossRefGoogle Scholar
  57. 57.
    AstraZeneca Canada Inc. Fasenra (benralizumab) product monograph. Date of approval: March 27, 2018.Google Scholar
  58. 58.
    Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 2010;125(6):1237–44 e2.  https://doi.org/10.1016/j.jaci.2010.04.005.CrossRefGoogle Scholar
  59. 59.
    Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–96 e5.  https://doi.org/10.1016/j.jaci.2013.05.020.CrossRefGoogle Scholar
  60. 60.
    Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol. 2016;169(3):135–45.  https://doi.org/10.1159/000444799.CrossRefPubMedGoogle Scholar
  61. 61.
    Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–90.  https://doi.org/10.1016/S2213-2600(14)70201-2.CrossRefPubMedGoogle Scholar
  62. 62.
    FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–41.  https://doi.org/10.1016/S0140-6736(16)31322-8.CrossRefPubMedGoogle Scholar
  63. 63.
    Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–27.  https://doi.org/10.1016/S0140-6736(16)31324-1.CrossRefPubMedGoogle Scholar
  64. 64.
    Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59.  https://doi.org/10.1016/S2213-2600(18)30406-5.CrossRefPubMedGoogle Scholar
  65. 65.
    • Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–58 This study demonstrated an OCS-sparing effect with a median 75% reduction of OCS doses from baseline with benralizumab.Google Scholar
  66. 66.
    Steinke JW. Anti-interleukin-4 therapy. Immunol Allergy Clin N Am. 2004;24(4):599–614, vi.  https://doi.org/10.1056/NEJMoa1703501.CrossRefGoogle Scholar
  67. 67.
    Coyle AJ, Le Gros G, Bertrand C, Tsuyuki S, Heusser CH, Kopf M, et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol. 1995;13(1):54–9.  https://doi.org/10.1165/ajrcmb.13.1.7598937.CrossRefPubMedGoogle Scholar
  68. 68.
    Swart DA, Anders-Bartholo PM, Tocker JE. Effects of IL-4Rα blockade on lung inflammation and airway hyperresponsiveness using Mu317RAXMu, a murine surrogate for AMG 317, in a treatment model of cockroach allergen-induced asthma in mice. J Allergy Clin Immunol. 2008;121(2):S267.  https://doi.org/10.1016/j.jaci.2007.12.1061.CrossRefGoogle Scholar
  69. 69.
    Dupilumab (Dupixent) for Asthma. JAMA. 2019;321(10):1000-1.Google Scholar
  70. 70.
    Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66.  https://doi.org/10.1056/NEJMoa1304048.CrossRefPubMedGoogle Scholar
  71. 71.
    Wechsler ME. Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma. N Engl J Med. 2013;368(26):2511–3.  https://doi.org/10.1056/NEJMe1305426.CrossRefPubMedGoogle Scholar
  72. 72.
    Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.  https://doi.org/10.1016/S0140-6736(16)30307-5.CrossRefPubMedGoogle Scholar
  73. 73.
    Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.  https://doi.org/10.1056/NEJMoa1804092.CrossRefPubMedGoogle Scholar
  74. 74.
    Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–85.  https://doi.org/10.1056/NEJMoa1804093.CrossRefPubMedGoogle Scholar
  75. 75.
    • McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36(8):957–71.  https://doi.org/10.1007/s40273-018-0658-x This study highlights the notion that biologics are without significant cost and that a cost-effective approach should be considered when initiating therapy.CrossRefGoogle Scholar
  76. 76.
    Altman MC, Lenington J, Bronson S, Ayars AG. Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2017;5(4):1137–9.  https://doi.org/10.1016/j.jaip.2017.01.013.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Internal Medicine, Department of MedicineQueen’s UniversityKingstonCanada
  2. 2.Allergy Research UnitKingston General HospitalKingstonCanada
  3. 3.Division of Allergy & Immunology, Department of MedicineQueen’s UniversityKingstonCanada
  4. 4.Department of Biomedical and Molecular ScienceQueen’s UniversityKingstonCanada

Personalised recommendations